Everolimus for subependymal giant cell astrocytoma: 5-year final analysis. - Wikidata - awgldk - TriplyDB

Everolimus for subependymal giant cell astrocytoma: 5-year final analysis.

Everolimus for subependymal giant cell astrocytoma: 5-year final analysis.

http://www.wikidata.org/entity/Q37337337

about

Profile of everolimus in the treatment of tuberous sclerosis complex: an evidence-based review of its place in therapy Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study.Cutaneous manifestations of tuberous sclerosis complex and the paediatrician's role.mTOR, a Potential Target to Treat Autism Spectrum Disorder.Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide.mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders.An update on genomic-guided therapies for pediatric solid tumors.Functional validation of the oncogenic cooperativity and targeting potential of tuberous sclerosis mutation in medulloblastoma using a MYC-amplified model cell line.TFEB activation restores migration ability to Tsc1-deficient adult neural stem/progenitor cells.The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.Influence of seizures on early development in tuberous sclerosis complex.Improving Outcomes in Infantile Spasms: Role of Pharmacotherapy.Precision medicine in genetic epilepsies: break of dawn?Tuberous sclerosis complex: From molecular biology to novel therapeutic approaches.Pharmacogenomics in epilepsy.Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study.Pooled analysis of menstrual irregularities from three major clinical studies evaluating everolimus for the treatment of tuberous sclerosis complex.Updates from the Neuro-Oncology Section of the 2015 American Neurological Association Annual Meeting.Long-term treatment of epilepsy with everolimus in tuberous sclerosis.Tuberous sclerosis complex-associated CNS abnormalities depend on hyperactivation of mTORC1 and Akt.Sclerotic bone lesions as a potential imaging biomarker for the diagnosis of tuberous sclerosis complex.What are the true volumes of SEGA tumors? Reliability of planimetric and popular semi-automated image segmentation methods.Metabolomic studies identify changes in transmethylation and polyamine metabolism in a brain-specific mouse model of tuberous sclerosis complex.mTOR Signaling and Neural Stem Cells: The Tuberous Sclerosis Complex Model.Tuberous sclerosis complex: review based on new diagnostic criteria.A review on therapeutic drug monitoring of the mTOR class of immunosuppressants: everolimus and sirolimus

P2860

Q28078328-828B9345-7E92-49ED-8347-622F23819754 Q36063084-BB80C2B9-E087-4FE1-A89E-FE948212662A Q36326114-1A3DFC66-171F-459B-9CA2-6DA6434950F7 Q37350523-DB4DA8DF-04BA-4A4B-ACE6-8C68671D4068 Q37644172-A970E0EC-C98E-41B3-9BFF-B259329EB63A Q37697798-C26FDDAA-7FC7-4A0D-99F9-CEEBF4F6398C Q38673827-2B95AD12-1328-4E98-934F-4B9525FC4C8A Q38707680-95453B0D-93D7-418D-A8F4-7476230208FC Q38715345-B4361061-F4D4-46DB-8965-EB15EAEDA6ED Q38755497-4A0BC1AB-FB78-4401-B4F2-298A1FCE49C1 Q38811967-40D0EC8F-4427-4006-866F-371E3D467E38 Q38931988-8DF37DBD-FB2D-48A3-96C1-1438E912337D Q38990891-47EFFE0C-F4D2-4ECC-B336-F67C90AACEC8 Q38994919-9F24D9A8-2020-4AD8-99F0-78F412B69F0C Q39084353-C2EA02D0-1479-4024-AADC-EE22D2599312 Q41326032-2F3512AD-4CF0-4071-BDE0-4D1AFDB30A15 Q42375761-555DC226-1CDC-4ED1-B10A-B5EF09566244 Q42554908-45A14D75-A74F-4AF2-9C41-7C9D6D137F5E Q46836536-97B9794B-5C93-44EB-9D69-04AB27A3D548 Q47826350-9AB84458-6E06-49D7-B906-43302C93784E Q48223051-2C302B2C-DB05-439D-AFA5-6EA2C0296C1B Q48255078-B3A31A3D-1241-447E-BDD7-C40F2AC3789E Q52326182-38DABD2D-3A57-4D94-ADD1-A713621963CF Q54978861-748D15A5-AEAC-457B-B051-5E84DEF1F018 Q55277251-688016EC-3D30-4136-8A4A-82F20773FF81 Q56035477-FBEE8EC2-5C12-4BA4-93B8-CB7C0B2405E0

P2860

Everolimus for subependymal giant cell astrocytoma: 5-year final analysis.

http://www.wikidata.org/entity/Q37337337

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 18 September 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Everolimus for subependymal giant cell astrocytoma: 5-year final analysis.

@en

Everolimus for subependymal giant cell astrocytoma: 5-year final analysis.

@nl

type

label

Everolimus for subependymal giant cell astrocytoma: 5-year final analysis.

@en

Everolimus for subependymal giant cell astrocytoma: 5-year final analysis.

@nl

prefLabel

Everolimus for subependymal giant cell astrocytoma: 5-year final analysis.

@en

Everolimus for subependymal giant cell astrocytoma: 5-year final analysis.

@nl

P1433

Q37337337-1D1130D7-AA14-4FAB-962D-2F4D70A8E79D

P1476

Q37337337-C70BB02B-D443-406F-B675-6A25C643DF6D

P2093

Q37337337-339B9606-C0F4-449D-9E2C-900B6B270985

Q37337337-33A73496-50F2-4523-84E6-37393E809E18

Q37337337-384068AF-B6FD-4DD0-A1A0-53915F98E45D

Q37337337-4B267DA3-C612-4D59-A618-CB37707CD55E

Q37337337-6DA775E3-B654-401B-8726-863D10F9C91D

Q37337337-7319EC00-E7C8-4CCF-8B9F-DA4A3037C4BA

Q37337337-7C59C3E1-AD70-4040-B06D-7BF14C9E2DA5

Q37337337-ADCD5CDB-148F-43D0-9CDD-09CF83B363DD

Q37337337-B666ABF6-F1C4-4E87-8656-48B6A773F1D2

Q37337337-FFF723CF-744F-4E57-B46A-650574ACD21E

P2860

Q37337337-0AF00301-6B53-4B87-B90B-CB9A6E8E2ECF

Q37337337-0C11F8A8-6C00-406A-9190-6057C4887968

Q37337337-0C808EFB-C21E-48EA-A687-F22EE97835B8

Q37337337-19B1DE5A-5F1C-47D6-82EC-99C4E4C851E5

Q37337337-288CDCF9-0B35-4A8D-B20D-4C8F22FD2B49

Q37337337-2C37CAAD-5719-4DDD-A0BF-E95271A22656

Q37337337-368F8211-BA88-400E-AC9E-01BA435E42A6

Q37337337-3B5364FE-379C-41FD-AB3A-C096398A77B1

Q37337337-3F88B00F-3984-452B-8861-FF0D7E091818

Q37337337-5A3FC42F-7E0B-4DCD-8931-589731D5AFE7

P304

Q37337337-5BFF8696-7D29-4E4E-82DE-20794127CEC0

P31

Q37337337-40786A63-156C-4577-BA5D-F5B59E4BBCE6

P356

Q37337337-EE772E28-8FF7-4406-9159-36E04764AB2F

P433

Q37337337-C14F7F11-CC05-4088-8A0D-1ED3DE88991F

P478

Q37337337-6A7DEEAE-68B6-4A64-9977-DF7627C27967

P577

Q37337337-67C8C02C-FE75-4539-802F-2EAA8DDE07ED

P698

Q37337337-DA2492CA-3FB6-4E0D-8DB9-E446C98DCC38

P932

Q37337337-3C1FBC5F-FFB7-4F3C-A646-011BCD81865C

P356

P1433

Annals of Neurology

P1476

Everolimus for subependymal giant cell astrocytoma: 5-year final analysis.

@en

P2093

Cindy Tudor

http://www.w3.org/2001/XMLSchema#string

Darcy A Krueger

http://www.w3.org/2001/XMLSchema#string

David N Franz

http://www.w3.org/2001/XMLSchema#string

Karen Agricola

http://www.w3.org/2001/XMLSchema#string

Katherine Holland-Bouley

http://www.w3.org/2001/XMLSchema#string

Marguerite M Care

http://www.w3.org/2001/XMLSchema#string

Maxwell Mays

http://www.w3.org/2001/XMLSchema#string

Noah Berkowitz

http://www.w3.org/2001/XMLSchema#string

Sara Miao

http://www.w3.org/2001/XMLSchema#string

Séverine Peyrard

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of sirolimus in lymphangioleiomyomatosis.

New equations to estimate GFR in children with CKD

The TSC1-TSC2 complex: a molecular switchboard controlling cell growth

Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria

The tuberous sclerosis complex

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.

Everolimus in clinical practice in long-term liver transplantation: an observational study.

Diffusion features of white matter in tuberous sclerosis with tractography

Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference.

Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis

P304

929-938

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ANA.24523

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

78

http://www.w3.org/2001/XMLSchema#string

P577

2015-09-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26381530

http://www.w3.org/2001/XMLSchema#string

P932

5063160

http://www.w3.org/2001/XMLSchema#string